We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$5.15B
Cap. Flow %
-877.82%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$4.99B
2
MRK icon
Merck
MRK
+$24.8M
3
ABBV icon
AbbVie
ABBV
+$23.3M
4
AGN
Allergan Inc
AGN
+$23M
5
JNJ icon
Johnson & Johnson
JNJ
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 63.04%
2 Technology 5.1%
3 Industrials 3.71%
4 Energy 1.9%
5 Consumer Discretionary 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGTC
51
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.47M 0.59%
165,124
-45,600
-22% -$929K
AEGR
52
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.35M 0.57%
+160,000
New +$4.03M
XLV icon
53
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$3.34M 0.57%
48,853
– –
TRVN
54
DELISTED
Trevena, Inc.
TRVN
$3.29M 0.56%
880
+350
+66% +$1.16M
ACOR
55
DELISTED
Acorda Therapeutics
ACOR
$3.23M 0.55%
659
-1,000
-60% -$4.29M
CPRX
56
DELISTED
Catalyst Pharmaceutical
CPRX
$3.15M 0.54%
1,060,000
+374,500
+55% +$1.03M
MRNS
57
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.09M 0.53%
73,383
– –
UNP icon
58
Union Pacific
UNP
$174B
$3.06M 0.52%
25,689
-6,623
-20% -$760K
SGMO
59
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.04M 0.52%
+200,000
New +$2.43M
MGNX icon
60
MacroGenics
MGNX
$235M
$2.95M 0.5%
84,198
-23,583
-22% -$588K
ARWR icon
61
Arrowhead Research
ARWR
$11.9B
$2.95M 0.5%
+400,000
New +$2.72M
EIGR
62
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.94M 0.5%
335
-78
-19% -$453K
SAGE
63
DELISTED
Sage Therapeutics
SAGE
$2.92M 0.5%
79,724
-8,200
-9% -$306K
DRNA
64
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.91M 0.5%
+176,802
New +$2.04M
ALDR
65
DELISTED
Alder Biopharmaceuticals
ALDR
$2.91M 0.5%
100,000
-50,000
-33% -$897K
SNA icon
66
Snap-on
SNA
$21.2B
$2.89M 0.49%
21,140
+5,040
+31% +$661K
ESRX
67
DELISTED
Express Scripts Holding Company
ESRX
$2.88M 0.49%
+33,966
New +$2.65M
NPSP
68
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.86M 0.49%
80,000
-59,420
-43% -$1.77M
KERX
69
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.83M 0.48%
+200,000
New +$3.1M
PRQR icon
70
ProQR Therapeutics
PRQR
$243M
$2.82M 0.48%
130,000
-70,000
-35% -$1.06M
MDCO
71
DELISTED
Medicines Co
MDCO
$2.77M 0.47%
+100,000
New +$2.48M
OCRX
72
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.68M 0.46%
421,254
+100,000
+31% +$585K
ABUS icon
73
Arbutus Biopharma
ABUS
$857M
$2.65M 0.45%
+175,000
New +$3.02M
AERI
74
DELISTED
Aerie Pharmaceuticals
AERI
$2.58M 0.44%
88,516
-75,000
-46% -$1.9M
SRPT icon
75
Sarepta Therapeutics
SRPT
$1.57B
$2.53M 0.43%
+175,000
New +$2.96M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $5.15B in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Isramco Inc, cutting an estimated $4.99B.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.